GCG and type 2 diabetes mellitus: Another trial using glucagon-like peptide-1 (GLP-1) agonists in patients with type-2 diabetes in the “real world” found that over 67% of the participants lost more than 5% of their initial body weight at 72 weeks without explicitly offering lifestyle interventions, and mean weight loss was 2.2% (57).